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Aims. This phase II study explored activity/safety of front-line dose-dense chemotherapy in high-grade STS (soft tissue sarcoma)
patients and tested ezrin as prognostic factor. Patients and Methods. The protocol consisted of three cycles of doxorubicin (DOXO)
30mg/m2 on days 1–3 every 2 weeks, followed by three cycles of ifosfamide (IFO) 2.5g/m2 two hours a day on days 1–5 every
3 weeks, with GCSF support. Ezrin was assessed immunohistochemically. Results. Twenty patients, 13 metastatic and 7 locally
advanced, were enrolled. Median age was 39 years (25–60). Median dose intensities were 42mg/m2/week and 3.6g/m2/week for
DOXO and IFO, respectively. Grade 3/4 toxicities occurred in 18 patients. Response rate was 15% (3 of 20) by RECIST. Patients
younger than 45 years with locally advanced disease and synovial histology presented longer survival. A trend towards longer
survival was observed among ezrin-positive patients. Conclusions. This dose-dense schedule should not be routinely used due to
its high frequency of toxic events; however, a sequential strategy with DOXO and IFO may beneﬁt selected patients and should be
further explored with lower doses. The role of ezrin as a prognostic marker should be conﬁrmed in a larger group of patients.
1.Introduction
High-grade, advanced, soft-tissue sarcoma (STS) is an ag-
gressive disease with poor prognosis. In this population,
single-agent doxorubicin (DOXO) has been considered the
standard in detriment of combination regimens [1]. On the
other hand, in view of the fact that STS patients main-
tain response to ifosfamide (IFO) after DOXO failure [2],
the sequential regimen emerges as a useful tool in an at-
tempt to enhance treatment eﬃcacy through better compli-
ance.
Testing this strategy, the ﬁrst sequential (dose dense) STS
study was shown to be feasible with manageable toxicity [3].
Thesecondone,nonetheless,observednosurvivaladvantage
over single-agent DOXO [4]. However, unselected patient
population might have obscured a potential beneﬁt from the
use of DOXO and IFO. Supporting this idea, a meta-analysis
of adjuvant chemotherapy in STS has shown that survival
beneﬁt was restricted to patients exposed to both agents [5].
Therefore, it is essential to identify those patients in whom
this strategy is worthwhile, particularly the ones with higher
risk of death.2 Sarcoma
In this scenario, one STS trial has demonstrated that
patients with positive ezrin expression presented poor sur-
vival [6]. Ezrin is a member of the ERM (ezrin/radixin/moe-
sin) family of cytoskeleton-associated proteins [7] involved
in cell to the extracellular matrix, as well as in cell-cell inter-
actions, receptor tyrosine-kinase signaling, transduction,
and interactions with apoptotic machinery [8, 9]. Enhanced
ezrin expression had been correlated with clinical stage and
metastatic behavior of rhabdomyosarcoma cells [10]. In
another study, ezrin was found to be necessary for metastasis
and survival in a mouse model of osteosarcoma [11].
The present study explored the activity and safety of
front-line sequential dose-dense DOXO- and IFO-based
chemotherapy in advanced, high-grade STS adult patients in
an outpatient basis, and we tried to conﬁrm if ezrin could
identify those patients with worse prognosis. The primary
endpointofthetrial,responserate,wasevaluatedbyRECIST
version 1.0 [12]. Secondary endpoints were overall survival,
progression-free survival, safety, and treatment compliance.
Toxicity proﬁle was categorized according to the National
Cancer Institute Common Toxicity Criteria version 2.0.
2. Patientsand Methods
2.1. Patient Selection. This study included metastatic
(META) or locally advanced (LOCA), chemotherapy-na¨ ıve,
histologically conﬁrmed, high-grade STS patients according
totheWHOclassiﬁcation.Patientsweredeemedeligiblewho
were 18–60 years of age, had at least one unidimensionally
measurablelesion, an ECOG performancestatus of 0–2, ade-
quate bone marrow, and renal, liver, and cardiac functions
(neutrophils count >1.0 × 109 per liter and left ventricle
ejection fraction >55%). Patients with malignant mesothe-
lioma, juvenile types of rhabdomyosarcoma, neuroblastoma,
PNET/Ewing, carcinosarcoma, and gastrointestinal stromal
tumor were excluded.
The protocol was reviewed and approved by the Ethics
Committee for Research Project Analysis from University
of Sao Paulo, and conducted according to the International
ConferenceonHarmonizationGoodClinicalPracticeguide-
line. All participants were advised about the procedures and
gave informed consent.
2.2. Trial Design. As cited previously, all chemotherapy
was administered on an outpatient basis. Three cycles of
30mg/m2/day in bolus DOXO on days 1–3, q2w, were fol-
lowed by three cycles of two-hour infusions of 2.5g/m2/day
I F Oo nd a y s1 – 5 ,q 3 w .M e s n ae q u i m o l a rt oI F Ow a s
administered in two half doses given immediately before
and 4 hours after IFO. Each cycle was followed by G-CSF
300µg/day for 7 days. Echocardiograms and scanned images
of the primary tumor and metastatic lesions (CT and/or
MRI) were taken before treatment, between DOXO and IFO
cycles, and after the ﬁnal IFO cycle. Dosage was reduced
20% whenever nonhematological grade 3/4 or hematological
grade 4 toxicity occurred.
2.3. Statistical Design. This trial required 39 patients to
achieve 80% statistical power at a signiﬁcance level of
P<. 05 in detecting a 20% increase from the expected re-
sponse rate of 30%. With the minimax two-step design [13],
six responses among the ﬁrst 19 patients were required in
ordertoaccrualtheentirecohort.Allsubgroupanalyseswere
univariate due to the limited number of patients included in
this trial.
2.4. Ezrin Expression. Ezrin was analyzed immunohisto-
chemically on formalin-ﬁxed, paraﬃn-embedded biopsy
slides as described elsewhere [6]. Brieﬂy, sections were
incubated overnight with antiezrin antibody (clone 3C12,
NeoMarkers), and they were then exposed to biotinylated
secondary antibody and avidin-biotin-peroxidase (LSAB,
K690, Dako). Slides from placenta served as controls using
the same procedures with and without the primary antibody.
Cytoplasmic immunostaining in least 1% of tumor cells was
scored as positive.
3. Results
3.1. Patient Characteristics. In this uni-institutional, single-
arm phase II study, 25 patients with high-grade STS were
screened between August 2005 and January 2007, and 20
entered (Figure 1). Thirteen patients had META disease
and seven had LOCA disease (ﬁve of these LOCA patients
presented with neurovascular involvement; Table 1). The
median length of time from initial diagnosis until inclusion
in the trial was 2.4 months (0.6–30 months).
3.2. Treatment Compliance. In total, 105 cycles were deliv-
ered, 54 during the ﬁrst phase and 51 during the second.
Fourteen patients (70%) received all planned chemotherapy.
Six META patients did not complete the protocol; this was
due to disease progression in three patients, two early deaths
(see discussion below), and in one patient DOXO was halted
after a single cycle due to unexplained cough. This patient
presented a pretreatment left ventricle ejection fraction
(LVEF) of 58% and diﬀuse myocardial hypocontractility.
He underwent a new LVEF evaluation, which remained
unchanged; he became asymptomatic and received six IFO
c y c l e sa tad o s eo f1 0 g / m 2 at the investigators’ discretion.
He presented stable disease and underwent resection of lung
metastases.
A median of six cycles (1–7) were administered per pa-
tient. Median dose intensities for DOXO and IFO for the
entire cohort were 42mg/m2/week (27–45) and 3.6g/m2/
week (1.3–4.1), respectively, which corresponded to 93%
(61–101%) and 87% (32–100%) of the planned dose inten-
sities.
3.3. Objective Response. In an intention-to-treat analysis, we
observedthreepartialresponses,10stablediseases,andseven
disease progressions, translating to a response rate of 15%
(3 out of 20). As mentioned previously, because this fell
short of the six responses required to complete accrual, the
study closed accrual on January 31st 2007. The histologicSarcoma 3
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Figure 1: Patient inclusion. LVEF: left ventricular ejection fraction. PE: pulmonary embolism. PR: partial response. PD: progressive disease.
subtypes of the patients who presented partial responses
were synovial sarcoma, unclassiﬁed sarcoma, and malignant
ﬁbrous histiocytoma (MFH). Median duration of response
was 2.1 months (1.3–4.9).
3.4. Progression-Free and Overall Survival. Survival infor-
mation was locked on August 31st 2007. After a median
follow-up of 11 months with 10 patients remaining alive,
progression-free survival (PFS) and overall survival (OS)
were 8.1 months (1.5–22.6) and 20.1 months (2.3–22.6),
respectively. Subgroup analyses showed longer PFS for those
patients in the LOCA group as compared to META patients,
not reached versus 6 months, HR 0.07 (95% CI 0.04–0.43)
P = .0005. OS was also longer among LOCA versus META
patients, not reached versus 8.6 months, HR 0.12 (95% CI
0.06–0.78) P = .01. No synovial sarcoma patients had died
at the time of survival analysis which translated to longer
survival in comparison to other histologies, OS not reached
versus 14.2 months, HR 0.00 (95% CI 0.05–0.78) P = .02.
The same was true for those patients younger versus older
than 45 years old, OS 20.1 months versus 4.2 months, HR
0.32 (95% CI 0.03–0.99) P = .04.4 Sarcoma
Table 1: Patient characteristics.
METAa LOCAb Total
N (%) N (%) N (%)
Total 13 (65) 7 (35) 20 (100)
Sex
Male 7 (35) 5 (25) 12 (60)
Female 6 (30) 2 (10) 8 (40)
Age (years)
Median 47 28 39
Range 26–60 25–45 25–60
Performance status
04 4 8
16 3 9
23 0 3
Histological subtype
Synovial 1 4 5
Leiomyo 5 0 5
Unclassiﬁed 2 2 4
Malignant ﬁbrohistiocytoma 2 0 2
Myxoid 1 1 2
Otherc 11 2
Primary site
Lower limbs 3 5 8
Retroperitoneal 5 0 5
Upper limbs 2 2 4
Otherd 30 3
Size of primary tumor (cm)
Median 12.4 11.7 12
Range 2–18 6.1–15 2–18
Metastatic site
Lung 11 NA 11
Lymph node 5 NA 5
Liver 4 NA 4
Bone 4 NA 4
Othere 4N A 4
Number of metastatic sites
15 N A 5
23 N A 3
≥35 N A 5
aMETA: metastatic disease.
bLOCA: locally advanced disease.
cEpithelioid, malignant peripheral nerve sheath tumor.
dLung, uterus, scalp.
eSpleen, adrenal gland, pleura.
NA: not applicable.
3.5. Adverse Events, Serious Adverse Events and Deaths. The
toxicities that occurred in more than 10 cycles are detailed in
Table 2. Grade 3–4 toxicities, predominantly hematological,
occurred in 76 of 105 cycles. Only one nonhaematologic
grade 4 toxicity (colitis) was observed. One grade 1 and
one grade 2 spontaneously reversible encephalopathies were
observed. No creatinine elevation was observed; however,
one IFO-inducible grade 3 haematuria occurred, requiring
Table 2: Adverse events occurring in more than 10 cycles.
Event
Grade 1–4-related events (N)
1234
Nonhaematological
Alopecia 7 12 NA NA
A n o r e x i a 6600
A s t h e n i a 11 64 0
Canalicular enzymes 34 5 2 0
Constipation 5 16 1 0
Dermatitis 9 5 0 0
Diarrhea 7 1 3 0
D y s g e u s i a 8500
Haematuria 12 2 2 0
Hypobicarbonatemia 13 0 0 0
Mucositis 17 12 3 0
Nausea 23 15 3 0
Transaminitis 18 3 1 0
Vomiting 20 8 6 0
Hematological
Anemia 41 20 5 0
Thrombocytopenia 7 3 2 0
Febrile Neutropenia NA NA 5 1
NA: not applicable.
dose reduction as previously described. A single toxic death
occurred in a 60-year-old patient with an MFH primary of
the shoulder, who died due to grade 4 colitis 1.9 month
after the third DOXO cycle. Three early deaths occurred
without signs of toxicity: the ﬁrst was a 59-year-old patient
with an unclassiﬁed sarcoma primary of the pelvis who
died as a consequence of lung metastases after receiving
one DOXO cycle; the second was a 58-year-old patient with
MFH primary of the thigh who died suddenly within three
weeks after completing the protocol; and the third was a 47-
year-old patient with an unclassiﬁed sarcoma primary of the
lung who died of pulmonary embolism after one IFO cycle.
Five other patients presented nonfatal thromboembolic
complications: two grade 3 deep vein thromboses (DVT),
one grade 4 pulmonary embolism in the META group, and
two grade 3 DVT in the LOCA group. All DVT cases were
documented in the primary lesion limb. Among 16 evaluable
patients, three presented cardiotoxicity, two grade 1, and one
grade 3.
3.6. Ezrin Expression. Ezrin expression was positive in 10
patients (Table 3). There was no correlation between ezrin
positivity and either response or presence of necrosis.
U n e x pect edl y ,a llﬁ v es y n o vi a ls a r c o m ap a ti e n t sw e r epo s i ti v e
for ezrin, correlation that has demonstrated to be statistically
signiﬁcant (Fisher’s exact test, P = .03). As illustrated in
Figure 2, a trend toward longer survival was observed among
ezrin positive versus negative patients, 21.1 months versus
8.6 months, HR 0.39 (95% CI 0.08–1.31) P = .11.Sarcoma 5
Table 3: Ezrin expression according to histology.
Histology Ezrin expression
Leiomyosarcoma + ++
Leiomyosarcoma 0
Leiomyosarcoma 0
Leiomyosarcoma 0
Leiomyosarcoma 0
Synovial + + ++
Synovial + ++
Synovial ++
Synovial +
Synovial +
Unclassiﬁed ++
Unclassiﬁed 0
Unclassiﬁed 0
Unclassiﬁed 0
MFHa +
MFHa 0
Myxoid + ++
Myxoid 0
Epithelioid +
MPNSTb 0
aMalignant ﬁbrohistiocytoma.
bMalignant peripheral nerve sheath tumor.
4. Discussions
In this phase II study investigating a sequential dose-
dense DOXO/IFO schedule in high-grade STS patients, a
low response rate has been observed, determining patients’
accrual discontinuation. Unexpectedly, none of the LOCA
patients responded; however, all but one was alive at the time
of study closure. On the other hand, two of the three patients
presenting partial response had died, raising the question
whetherresponseratewillrepresentanappropriateendpoint
in future STS trials.
Despite a high degree of grade 3/4 toxicities observed,
febrile neutropenia rate was similar to that observed in the
literature [14], and this occurred irrespective of the lower
neutrophil threshold and less GCSF support [3, 14]. GCSF
usehasbeenimplicatedinpooroutcome[15].Theincidence
of cardiotoxicity was not higher than that observed in the
literature [3, 14]; however, a great number of thromboem-
bolic complications may suggest that mechanical factors and
changes in procoagulant systems after chemotherapy [16]
might have been boosted by dose density and should be used
with caution. IFO administration over 2 hours in ﬁve days
may result in less renal and neurologic complications. All
these nuances have practical implications.
The median OS was longer than those described in two
previous studies with similar dose-dense strategies [3, 4].
We have included more resectable patients, more synovial
h i s t o l o gy ,a n dw eh a v ee x c l u d e ds u b t yp e ss u c ha sc a r c i n o s a r -
coma and clear cell sarcoma which are known to be, respec-
tively, sensitive to cisplatin [17] (absent in this protocol) or
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Figure 2:Overallsurvivalaccordingtoimmunohistochemicalezrin
expression.Medianoverallsurvivalforsoft-tissuesarcomaspatients
whose tumors were classiﬁed as positive for ezrin was 21.1 months,
compared to 8.6 months for ezrin-negative patients; HR 0.39, 95%
CI 0.08–1.31; P = .11.
irresponsive to systemic treatment [18]. Additionally, in one
of the earlier trials [4], prophylactic use of erythropoietin
may have detrimentally inﬂuenced OS [19]. Statistical lim-
itations, along with heterogeneity of patient populations,
preclude drawing ﬁrm conclusions through direct com-
parison to these dose-dense studies. Nevertheless, we have
found selected patients who presented longer survival in our
population, nonetheless we know that this would unlikely
hold up on a multivariate analysis, underpowered because of
small number of patients. If this was due to this sequential
approach using both agents DOXO and IFO may be consid-
ered an issue of debate.
In a scenario of doubts in which STS trials are inserted,
some questions arise. (1) Are there patients who might
beneﬁt from DOXO and IFO in ﬁrst-line chemotherapy?
(2) Are these patients among the ones with poor prognosis?
(3) How could we ﬁnd them? The answer for the ﬁrst two
questions is “perhaps” and for the third one, we will use
selected histologic subtypes as examples. Leiomyosarcoma
patients may show response rate (RR) as low as zero [20],
in contrast to synovial sarcoma ones that may be especially
sensitive to ifosfamide with RR as high as 100% [21]. In this
setting, tumor size and grade have been considered the most
important prognostic factors; however, even those patients
with the same histology-size-grade-tumors experience dis-
crepant survivals. In an eﬀort to reduce this limitation, the
incorporation of gene expression analyses has permitted the
improvement in diagnosis [22], prognosis prediction [23–
25], and the identiﬁcation of new molecular targets that
may be used for the development of new drugs [26]. The
new era of molecular-target-driven treatment has shown
that survival beneﬁt is missed when unselected patient
populationistreated.Thisisundoubtedlyapplicableforsoft-
tissue sarcoma trials.6 Sarcoma
Wehaveobservedthat,besidesbeing100%ezrinpositive,
those patients with synovial histology had most often locally
advanced disease (with a better prognosis than metastatic
disease), and we believe that this clearly confounds this data.
However,wealsobelievethatezrinmayhavepositively inﬂu-
enced survival among those patients. Corroborating these
results, a better outcome was also observed for patients with
ovarian cancer and positive for ezrin [27]. This is in contrast
to the earlier STS report [6]; however, a possible explanation
for this latter discrepancy may be the approximately 70%
malignantﬁbrohistiocytomahistologycomprisingthatstudy
population [6]. In agreement with our results, the only
patient with synovial histology in the earlier trial who was
ezrin-positivepresented16monthsOS,anoutcomethatmay
be considered favorable. Moreover, one ezrin-positive leiom-
yosarcomapatientincludedinourstudyhad14.2monthOS,
compared to the median 8.2 months of four ezrin-negative
ones.Thisraisesthehypothesisofadifferentialroleplayedby
ezrin in each STS histology. The role of ezrin as a prognostic
indicator should be conﬁrmed in future prospective STS
trials in larger populations.
In accordance to the literature [4], we conclude that se-
quential dose-dense DOXO- and IFO-based chemotherapy
does not appear suitable for routine treatment of high-grade
advanced STS patients. However, this sequential strategy
withDOXOfollowedbyatwo-hourifosfamideregimendoes
warrant further investigation in lower doses, trying to ﬁnd
the balance between eﬃcacy and safety.
The fact that STS are heterogeneous and cannot be
grouped and treated as the same way is the new paradigm. In
the near future, the identiﬁcation of one (or more) biologic
(molecular) marker(s) will tailor treatment in an attempt to
predict compliance, response, and survival.
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